文献速递银屑病与炎症性皮肤病

日本斑块状银屑病患者中依奇珠单抗治疗退出与再治疗的长期疗效与安全性:开放标签III期研究(UNCOVER-J)结果

Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-11-13

UNCOVER-J开放标签III期单臂研究纳入78例日本斑块状银屑病患者,依奇珠单抗治疗52周后70例达PASI75并停药至100周。停药后87%复发,中位复发时间143天;再治疗12周后83%重获PASI75,疗效维持至再治疗120周。

要点

  • 依奇珠单抗治疗52周时PASI75应答率100%,停药至100周降至7%。
  • 停药后87%患者复发,中位复发时间143天,约半数在5个月内复发。
  • 再治疗12周后83%患者重获PASI75,应答维持至再治疗120周。

核心结论

  • 达到PASI75后停用依奇珠单抗的患者约半数在5个月内复发,但多数在再治疗12周内重获应答,且应答维持至再治疗120周。

研究设计与样本

  • 单臂开放标签III期研究(UNCOVER-J;NCT01624233),纳入78例日本斑块状银屑病患者。
  • 依奇珠单抗160 mg负荷剂量,前12周每2周80 mg,之后每4周80 mg(IXE Q4W)至第52周。
  • 第52周达PASI75的70例患者从第52周至第100周停药;停药期复发(PASI ≤50)者以IXE Q4W再治疗192周。

主要发现

  • 第52、76、100周PASI75应答率分别为100%、26%、7%;PASI90分别为87%、11%、3%;PASI100分别为53%、0%、0%。
  • 停药后87%患者复发,中位复发时间143天。
  • 再治疗12周后,83%复发患者达PASI75,68%达PASI90,25%达PASI100;改善维持至再治疗120周。
  • 停药期治疗中出现的不良事件和严重不良事件分别报告于56%和4%的患者,再治疗期分别为88%和14%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term management of moderate-to-severe psoriasis is usually discussed in terms of continuous administration; however, there are many situations in clinical practice where treatment may be withdrawn with subsequent retreatment. OBJECTIVE: To assess the clinical course after ixekizumab treatment withdrawal and retreatment, as well as the effectiveness of ixekizumab retreatment, in Japanese patients with plaque psoriasis. METHODS: This single-arm, open-label study (UNCOVER-J; NCT01624233) comprised 78 patients with plaque psoriasis. After ixekizumab treatment (160-mg loading dose, 80 mg every 2 weeks for the first 12 weeks, and then 80 mg every 4 weeks (IXE Q4W) until Week 52), 70 patients achieved a Psoriasis Area Severity Index (PASI)75 response at Week 52. These 70 patients withdrew from ixekizumab treatment from Weeks 52 to 100. Patients who relapsed (PASI ≤50) during the Treatment Withdrawal Period were retreated with IXE Q4W for 192 weeks. RESULTS: At Weeks 52, 76 and 100, PASI75 response rates were 100%, 26% and 7%; PASI90 response rates were 87%, 11% and 3%; and PASI100 response rates were 53%, 0% and 0%. After treatment withdrawal, 87% of patients relapsed; median time to relapse was 143 days. After 12 weeks of retreatment with IXE Q4W, 83% of relapsed patients achieved PASI75, 68% achieved PASI90 and 25% achieved PASI100; improvements were maintained up to 120 weeks of retreatment. Treatment-emergent adverse events and serious adverse events were reported in 56% and 4% of patients during the Treatment Withdrawal Period, and in 88% and 14% of patients during the Retreatment Period. CONCLUSION: In patients withdrawn from ixekizumab after achieving PASI75, approximately half relapsed within 5 months of withdrawal; however, most patients recaptured response within 12 weeks, and response was maintained for up to 120 weeks of retreatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Umezawa Y, Torisu-Itakura H, Morisaki Y, et al. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. J Eur Acad Dermatol Venereol. 2018. PMID: 30325534. doi:10.1111/jdv.15292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。